Literature DB >> 7823075

An improved diagnostic assay for Lambert-Eaton myasthenic syndrome.

M Motomura1, I Johnston, B Lang, A Vincent, J Newsom-Davis.   

Abstract

A new immunoprecipitation assay has been established for detecting antibodies to voltage-gated calcium channels (VGCCs) in Lambert-Eaton myasthenic syndrome (LEMS), using 125I-omega-conotoxin MVIIC, which binds to P-type VGCCs, to label extracts of human cerebellum. Fifty six of 66 serum samples (85%) from patients with clinically and electrophysiologically definite LEMS were positive for the presence of VGCC antibodies, defined as a titre > 3 SD above the mean for the healthy controls (n = 10). All disease controls (n = 40) were negative. This sensitive immunoassay should prove valuable in the diagnosis of LEMS.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7823075      PMCID： PMC1073275          DOI： 10.1136/jnnp.58.1.85

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  14 in total

1.  Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.

Authors:  K Leys; B Lang; I Johnston; J Newsom-Davis
Journal:  Ann Neurol       Date:  1991-03       Impact factor: 10.422

2.  Blocking and isolation of a calcium channel from neurons in mammals and cephalopods utilizing a toxin fraction (FTX) from funnel-web spider poison.

Authors:  R Llinás; M Sugimori; J W Lin; B Cherksey
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

3.  Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome.

Authors:  E Sher; C Gotti; N Canal; C Scoppetta; G Piccolo; A Evoli; F Clementi
Journal:  Lancet       Date:  1989-09-16       Impact factor: 79.321

4.  Quantal components of end-plate potentials in the myasthenic syndrome.

Authors:  E H Lambert; D Elmqvist
Journal:  Ann N Y Acad Sci       Date:  1971-09-15       Impact factor: 5.691

5.  Autoantibody specificities in Lambert-Eaton myasthenic syndrome.

Authors:  B Lang; I Johnston; K Leys; G Elrington; B Marqueze; C Leveque; N Martin-Moutot; M Seagar; T Hoshino; M Takahashi
Journal:  Ann N Y Acad Sci       Date:  1993-06-21       Impact factor: 5.691

6.  Effects of omega-conotoxin GVIA on autonomic neuroeffector transmission in various tissues.

Authors:  A De Luca; C G Li; M J Rand; J J Reid; P Thaina; H K Wong-Dusting
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

7.  Autoantibodies bind solubilized calcium channel-omega-conotoxin complexes from small cell lung carcinoma: a diagnostic aid for Lambert-Eaton myasthenic syndrome.

Authors:  V A Lennon; E H Lambert
Journal:  Mayo Clin Proc       Date:  1989-12       Impact factor: 7.616

8.  Heterogeneity of calcium channel autoantibodies detected using a small-cell lung cancer line derived from a Lambert-Eaton myasthenic syndrome patient.

Authors:  I Johnston; B Lang; K Leys; J Newsom-Davis
Journal:  Neurology       Date:  1994-02       Impact factor: 9.910

9.  Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.

Authors:  A Vincent; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

10.  P-type voltage-dependent calcium channel mediates presynaptic calcium influx and transmitter release in mammalian synapses.

Authors:  O D Uchitel; D A Protti; V Sanchez; B D Cherksey; M Sugimori; R Llinás
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205
View more
  39 in total

1.  P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments.

Authors:  Nicholas L Zalewski; Vanda A Lennon; Daniel H Lachance; Christopher J Klein; Sean J Pittock; Andrew Mckeon
Journal:  Muscle Nerve       Date:  2016-02-08       Impact factor: 3.217

2.  Antibodies to acetylcholine receptors in patients with different clinical forms of myasthenia and Lambert-Eaton myasthenic syndrome.

Authors:  D V Sidnev; M Yu Karganov; N I Shcherbakova; I B Alchinova; A G Sanadze
Journal:  Neurosci Behav Physiol       Date:  2007-02

3.  Mild clinical expression of Lambert-Eaton myasthenic syndrome in a patient with HIV infection.

Authors:  André Truffert; Gilles Allali; Natalia Vokatch; Patrice H Lalive
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-08       Impact factor: 10.154

4.  Antineuronal antibodies in sporadic late-onset cerebellar ataxia.

Authors:  K Bürk; M Wick; G Roth; P Decker; R Voltz
Journal:  J Neurol       Date:  2009-07-24       Impact factor: 4.849

Review 5.  Metabolism and trafficking of N-type voltage-operated calcium channels in neurosecretory cells.

Authors:  E Sher; P Rosa; M Francolini; A Codignola; E Morlacchi; E Taverna; F Giovannini; A Brioschi; F Clementi; M W McEnery; M Passafaro
Journal:  J Bioenerg Biomembr       Date:  1998-08       Impact factor: 2.945

6.  Autonomic dysfunction in Lambert-Eaton myasthenic syndrome.

Authors:  S A Waterman
Journal:  Clin Auton Res       Date:  2001-06       Impact factor: 4.435

Review 7.  Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain.

Authors:  R B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

8.  Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome.

Authors:  P Maddison; J Newsom-Davis; K R Mills
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

9.  Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer.

Authors:  P Maddison; B Lang; K Mills; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-02       Impact factor: 10.154

10.  Autoantibodies in neuromuscular transmission disorders.

Authors:  Angela Vincent
Journal:  Ann Indian Acad Neurol       Date:  2008-07       Impact factor: 1.383
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.